Add Formweb to your mobile device
Search results for:
fosaprepitant
fosaprepitant
Brand names: Emend for Injection
| Form | Strength |
|---|---|
| POWDER FOR INJECTION, INTRAVENOUS | 150 mg |
Last updated: Dec. 1, 2025
fosaprepitant
| Form | Strength |
|---|---|
| POWDER FOR INJECTION, INTRAVENOUS | 150 mg |
Inpatient Formulary, Restricted for the prevention and treatment of nausea and vomiting in moderate and highly emetogenic therapy and for refractory cyclic vomiting syndrome.
Restricted to severe acute CVS episode after a trial of 5-HT3 antagonists (ondansetron) and fluids. NSAIDS and triptans should be trialed first for acute CVS episodes in patients with personal or family history of migraine.
Fosaprepitant IV is preferred over oral aprepitant, for the first dose, if patient has IV access.